Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

      
20/8 17:17
af Helge Larsen/PI-redaktør
This session have ended.
20/8 17:17
af Jan Van de Winkel
You are very welcome. We truly enjoyed this stimulating session and cannot wait for the next one. Thanks.
20/8 17:16
af Helge Larsen/PI-redaktør
Thank You for joining us and thank you for the many fullfilling answers to our questions. We look forward to seeing you back here on ProInvestor.com after Q3 .
20/8 17:16
af Jan Van de Winkel
But we are in excellent position to reach our inspirational 2025 vision, having a strong company with an amzing talent base and a growing income stream and above all the support of loyal intelligent and stimulating investors behind us.
20/8 17:15
af Jan Van de Winkel
We have an ambition to further build Genmab into an iconic biotechnology company, and the prospects have never looked as strong as today. It is not possible to comment on how the market will develop over the coming years...
20/8 17:14
af Solsen
Mr Winkel You have several times expressed that your goal is to bring Genmab on level with ex Regereron and a value arround $40 bn. Do you belive its in the timeline with your vision period 2025.
20/8 17:14
af Helge Larsen/PI-redaktør
And now to the last question.
20/8 17:13
af Jan Van de Winkel
Thank you for the kind notes. We firmly believe that a dual listing is optimal to get a broader investor base. With the succesful US listing, we hope to further raise the profile of Genmab as an antibody innovation powerhouse.
20/8 17:12
af Budweis
As an long term investor I will thank you Jan for an amazing journey. What is your long term plan with the US listing? Could it be an idea to be listed 100% in US?
20/8 17:11
af Jan Van de Winkel
Once the data is available and we have established a safe and effective dose, it is certainly possible to broaden the target base for this molecule.
20/8 17:11
af Jan Van de Winkel
At present we are focusing clinical development of HexaBody DR5/DR5 in solid tumors...
20/8 17:10
af Solsen
Mr Winkel. Obviously DR5xDR5 have effect in MM and especially in RRMM. Do you have plans for trials in these indications or do any agreement with JNJ hold you from doing that ?
20/8 17:09
af Jan Van de Winkel
No further news at this time.
20/8 17:09
af Bulder
Any news on the potential revival of sc dara in solid tumors, that was mentioned on JnJ Pharma Day in May?
20/8 17:09
af Jan Van de Winkel
You can expect a company announcement from Genmab once the data from the ASCLEPIOS studies become available.
20/8 17:09
af Jan Van de Winkel
You can expect a company announcement from Genmab once the data from the ASCLEIPIOS stud
20/8 17:08
af Bulder
Can we expect a company announcement with top line Asclepios data before publication of the Ectrims abstract on Sept 11?
20/8 17:07
af Jan Van de Winkel
We hope to soon present the very strong preclinical data with HexaBody CD38 at a scientific conference.
20/8 17:07
af Jan Van de Winkel
Timing is thus unclear. We will update the market once HexaBody CD38 is ready for clinical evaluation...
20/8 17:06
af Jan Van de Winkel
However, Janssen does not have to wait until all the data is collected and could exercise their option after only a few patients treated if the data is striking...
20/8 17:06
af Jan Van de Winkel
The deal structure on HexaBody CD38 dictates that Janssen can await the results of two clinical studies, one in MM and one in DLBCL before exercising their option to further develop this exciting asset...
20/8 17:04
af Solsen
Mr Winkel. The hexa-CD38 deal with Janssens having a decision point with PoC. Could you put a timeline to that ?
20/8 17:04
af Jan Van de Winkel
We are still dose escalating DuoBody CD3xCD20 and have already observed signs of biologic activity. Hopefully, we can present early data from the first clinical trial at a medical conference in 2019.
20/8 17:03
af Solsen
Mr Winkel Now more pts have been testet in CD20xCD3 trial can you tell us how the silenced arm er doing ?
20/8 17:03
af Jan Van de Winkel
We are currently dose escalating HexaBody DR5/DR5 and expect to present a status update of the first clinical study in 2019.
20/8 17:02
af Solsen
Mr Winkel Hence DR5xDR5 are your own drug can you tell how many pts there is recruitet. And are the drug still a candidate for partnering. If positive then when can we expect this happen.
20/8 17:01
af Jan Van de Winkel
Another clear difference is that DARA is a fully human antibody, whereas Isatuximab is a humanized antibody, which may be less optimal for long term use in patients.
20/8 17:00
af Jan Van de Winkel
Preclinically the two ABs have very different mechanisms of action (DARA has a far broader MoA than Isatuximab)...
20/8 16:59
af Bulder
Are there clear differences between dara and isatuxumab besides the sc/IV infusion?
20/8 16:59
af Jan Van de Winkel
DARA has one of the cleanest safety profiles of all cancer drugs known to date. We continously monitor safety of this medicine.
20/8 16:58
af Bulder
What do we know about long term toxicities of dara?
20/8 16:58
af Jan Van de Winkel
It is too early to speculate on the dynamics of the future frontline treatment landscape.
20/8 16:57
af Bulder
Will the Griffin combo make people forgo transplant?
20/8 16:57
af Jan Van de Winkel
We only have information from the filing by Horizon Pharma in early July for a BLA, and have not heard feedback from the FDA.
20/8 16:56
af Bulder
Do we know a PDUFA date for the teprotumumab bla?
20/8 16:56
af Jan Van de Winkel
The published data for the SWOG 777 study shows a PFS of 43 months (VRD), whereas the initial data from MAIA indicates a PFS of around 58 months (or higher).
20/8 16:55
af Bulder
Why should DRd be any better than VRd? The SWOG study showed results similar to those of Maia.
20/8 16:54
af Jan Van de Winkel
As we released yesterday, the GRIFFIN data is very impressive and will be presented in full at the upcoming IMW meeting in Boston in September and may very rapidly be published in a peer-reviewed journal. On top of that, the D-RVD regimen may then be included in US compendia, and thus be reimbursed.
20/8 16:52
af Bulder
What are the chances that the D-RVd combination based on data from the Griffin study will be put on a compendia listing in the US and thus become used off label?
20/8 16:52
af Jan Van de Winkel
Genmab is very excited about working with CD47 ABs licensed from BliNK, and has excellent preclinical proof of concept studies performed with novel bispecific approaches.
20/8 16:51
af Jan Van de Winkel
Humminbird Bioscience has no access to the DuoBody technology platform...
20/8 16:50
af Sukkeralf
Are Hummingbird Bioscience still using the Duobody platform to make CD47 BsAbs - and if so are there any conflicts with your license agreement with BLiNK on CD47 antibodies for development of DuoBody BsAbs?
20/8 16:50
af Jan Van de Winkel
As an example, we can refer to the deal we entered into with Immatics last year.
20/8 16:50
af Jan Van de Winkel
We presently have one of the most innovative technology portfolios in this area and would be interested in further broadening our suite of technologies...
20/8 16:49
af Jan Van de Winkel
Genmab will continue to be focused on AB focused approaches for cancer...
20/8 16:48
af Sukkeralf
When Genmab is scouting opportunities to in-licensing complementing technologies - is it then in the antibody space or could it be other therapeutic modalities like vaccines, small molecules, peptides, CAR-T, gene therapy ect. ?
20/8 16:48
af Jan Van de Winkel
There are several studies which have a DARA maintenance arm in the protocol, so we anticipate news on DARATUMUMAB maintenance before the study finalises that you refer to.
20/8 16:47
af Sukkeralf
Janssen recently initiated a phase III study to examine daratumumab and lenalidomide as maintenance therapy in newly diagnosed patients with MM but could you elaborate on timelines for approval of daratumumab alone as maintenance ?
20/8 16:46
af Jan Van de Winkel
In our opinion, an antibody wihch has a weak therapeutic activity, is unlikely to become a competitive threat.
20/8 16:45
af Sukkeralf
Could MOR202 still become a minor competitor in China now they have partnered up with a more local biotech company (I-MAB Biopharma) ?
Nyeste Først- Ældste Først   Side 1/2